TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
P/B ratio for TELA Bio, Inc. (TELA)
P/B ratio as of 2023: 8.02
According to TELA Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.02. At the end of 2022 the company had a P/B ratio of 13.08.
P/B ratio history for TELA Bio, Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 8.02 |
| 2022 | 13.08 |
| 2021 | 9.22 |
| 2020 | 3.97 |
| 2019 | 4.77 |
| 2018 | -0.63 |
| 2017 | -0.80 |